IP Library Granted Patent US 10,941,209
Granted Patent B2
US 10,941,209 · App. 16/040,877 · Granted Mar 9, 2021

Identification and use of new tumor-promoting gene in hematological malignancies

Inventors: Ulrich Steidl (New Rochelle, NY); Christian Steidl (North Vancouver, CA); Ujunwa Cynthia Okoye-Okafor (Bronx, NY)
Assignees: Albert Einstein College of Medicine; British Columbia Cancer Agency Branch
C07K16/32C12N15/113C12Q1/6886G01N33/57426C07K2317/30C12N2310/14C12N2310/531C12N2320/30C12Q2600/136C12Q2600/158G01N2500/04G01N2500/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,941,209
App. No.
16/040,877
Granted
Mar 9, 2021
Kind
B2
Abstract

Methods are provided for diagnosing and treating a blood cancer or a myelodysplastic syndrome in a subject. Associated compositions and kits therefor are also provided.

Claims (3)

1. A method of treating a hematological malignancy in a subject comprising administering to the subject an amount of an agent which inhibits expression of a BX648577 gene, or an amount of an agent which inhibits activity of an expression product of a BX648577 gene, so as to thereby treat the hematological malignancy, wherein the agent is an siRNA directed to a BX648577 gene or an RNA transcript thereof, or an shRNA directed to a BX648577 gene or an RNA transcript thereof.

2. The method of claim 1 , wherein the hematological malignancy is an acute myeloid leukemia.

3. The method of claim 1 , wherein the BX648577 gene encodes an mRNA encoding a protein having the sequence of SEQ ID NO: 1.

Assignments (1)
MERGER AND CHANGE OF NAME Recorded Feb 26, 2019
From: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.; ALBERT EINSTEIN COLLEGE OF MEDICINE
To: ALBERT EINSTEIN COLLEGE OF MEDICINE
Reel/Frame 048438/0275 →